Torsdag 31 Oktober | 11:08:39 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

Tid*
2025-02-26 - Bokslutskommuniké 2024
2024-11-22 - Kvartalsrapport 2024-Q3
2024-10-29 - Extra Bolagsstämma 2024
2024-08-22 - Kvartalsrapport 2024-Q2
2024-05-30 - X-dag ordinarie utdelning PMDS 0.00 SEK
2024-05-29 - Årsstämma
2024-05-28 - Kvartalsrapport 2024-Q1
2024-02-29 - Bokslutskommuniké 2023
2024-01-31 - Split PMDS 128:1
2023-12-29 - Extra Bolagsstämma 2023
2023-11-28 - Kvartalsrapport 2023-Q3
2023-08-30 - Kvartalsrapport 2023-Q2
2023-06-27 - Årsstämma
2023-05-24 - X-dag ordinarie utdelning PMDS 0.00 SEK
2023-05-23 - Kvartalsrapport 2023-Q1
2023-02-28 - Bokslutskommuniké 2022
2022-11-29 - Kvartalsrapport 2022-Q3
2022-08-30 - Kvartalsrapport 2022-Q2
2022-05-19 - X-dag ordinarie utdelning PMDS 0.00 SEK
2022-05-17 - Kvartalsrapport 2022-Q1
2022-05-17 - Årsstämma
2022-02-16 - Bokslutskommuniké 2021
2021-11-23 - Kvartalsrapport 2021-Q3
2021-08-24 - Kvartalsrapport 2021-Q2
2021-05-28 - X-dag ordinarie utdelning PMDS 0.00 SEK
2021-05-27 - Extra Bolagsstämma 2021
2021-05-27 - Kvartalsrapport 2021-Q1
2021-05-27 - Årsstämma
2021-02-23 - Bokslutskommuniké 2020
2020-11-24 - Kvartalsrapport 2020-Q3
2020-08-25 - Kvartalsrapport 2020-Q2
2020-05-27 - X-dag ordinarie utdelning PMDS 0.00 SEK
2020-05-26 - Årsstämma
2020-05-26 - Kvartalsrapport 2020-Q1
2020-02-18 - Bokslutskommuniké 2019
2019-11-22 - Kvartalsrapport 2019-Q3
2019-10-22 - Extra Bolagsstämma 2019
2019-08-27 - Kvartalsrapport 2019-Q2
2019-05-22 - X-dag ordinarie utdelning PMDS 0.00 SEK
2019-05-21 - Kvartalsrapport 2019-Q1
2019-05-21 - Årsstämma
2019-02-26 - Bokslutskommuniké 2018
2018-11-23 - Kvartalsrapport 2018-Q3
2018-08-20 - Kvartalsrapport 2018-Q2
2018-05-17 - X-dag ordinarie utdelning PMDS 0.00 SEK
2018-05-16 - Årsstämma
2018-05-16 - Kvartalsrapport 2018-Q1
2018-02-06 - Bokslutskommuniké 2017
2017-11-21 - Kvartalsrapport 2017-Q3
2017-08-30 - Kvartalsrapport 2017-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
PMD Device Solutions utvecklar och säljer medicinska produkter för andningsövervakning, för både sjukhus och hemvård. Dess primära produkt är RespiraSense, en lösning som används för att övervaka andningsfrekvensen och stödja upptäckten av patientförsämring, och för att undvika andningssvikt och ogynnsamma patientresultat. RespiraSense kommersialiseras i Europa, Storbritannien och är FDA godkänd i USA.
2024-10-29 14:10:00

Extraordinary general meeting of PMD Device Solutions AB (publ), reg. no 556639–6809 (the "Company"), was held today, 29 October 2024 at 10.00 CET in Stockholm. The meeting resolved, with required majority, on all proposed matters in accordance with the board's previously announced proposals. The following is a summary of the main decisions taken.

Amendment of the articles of association (number 1)

The meeting resolved to amend the articles of association in accordance with the below.

Current wordingProposed wording

§ 4 Aktiekapital / Share capital

Aktiekapitalet ska vara lägst 105 400 000 kronor och högst 421 600 000 kronor
The share capital shall be not less than SEK 105,400,000 and not more than SEK 421,600,000.

§ 4 Aktiekapital / Share capital

Aktiekapitalet ska vara lägst 86 436 000 kronor och högst 345 744 000 kronor.
The share capital shall be not less than SEK 86,436,000 and not more than SEK 345,744,000.

Decision to reduce the share capital without cancellation of shares for allocation to non-restricted equity (number 1)

The meeting resolved to reduce the Company's share capital by SEK 19,180,647.6 for allocation to non-restricted equity and without cancellation of shares. Following the reduction, the Company's share capital will amount to SEK 87,563,826 divided into 20,848,530 shares (before registration of the rights issue resolved in July 2024 (the ‘Rights Issue’)), each share with a quota value of SEK 4.2.

The decision to reduce the share capital can be implemented without obtaining the authorisation of the Swedish Companies Registration Office since the reduction, taking into account the Rights Issue, will not reduce the Company's restricted equity or its share capital.

Amendment of the articles of association (number 2)

The meeting resolved to amend the articles of association in accordance with the below.

Current wordingProposed wording

§ 4 Aktiekapital / Share capital

Aktiekapitalet ska vara lägst 86 436 000 kronor och högst 345 744 000 kronor.
The share capital shall be not less than SEK 86,436,000 and not more than SEK 345,744,000.

§ 4 Aktiekapital / Share capital

Aktiekapitalet ska vara lägst 25 000 000 kronor och högst 100 000 000 kronor.
The share capital shall be not less than SEK 25,000,000 and not more than SEK 100,000,000.


Decision to reduce the share capital without cancellation of shares for allocation to non-restricted equity (number 2)

The meeting resolved on a reduction of the Company's share capital by a maximum of SEK 83,197,755.4 for allocation to non-restricted equity. The reduction shall be carried out without cancellation of shares and to such extent within the framework of the maximum reduction amount that the quota value of the share changes to SEK 1.00 per share.

In order for the share capital reduction to be carried out to the maximum reduction amount of SEK 83,197,755.4 requires registration of the Rights Issue and the following directed share issue.

The reduction is carried out in order to increase the Company's flexibility in the utilisation of the Company's working capital and to create an appropriate quota value for the Company's share. After the reduction, the quota value of the Company's share is intended to amount to SEK 1.00 per share.

The decision to reduce the Company's share capital in accordance with this proposal requires authorisation from the Swedish Companies Registration Office or a general court. The Company intends to notify the resolution under this item for registration. Provided that the required authorisation is obtained, the reduction resolution is expected to be executed in January 2025.